JP2023134488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023134488A5 JP2023134488A5 JP2023101803A JP2023101803A JP2023134488A5 JP 2023134488 A5 JP2023134488 A5 JP 2023134488A5 JP 2023101803 A JP2023101803 A JP 2023101803A JP 2023101803 A JP2023101803 A JP 2023101803A JP 2023134488 A5 JP2023134488 A5 JP 2023134488A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- modified
- molecule according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 30
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 241000710929 Alphavirus Species 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 11
- 101800001603 Capsid protein C Proteins 0.000 claims 5
- 101800001847 Core protein precursor Proteins 0.000 claims 5
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 3
- 108010087302 Viral Structural Proteins Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 2
- 101800001643 6K protein Proteins 0.000 claims 1
- 101710201734 E3 protein Proteins 0.000 claims 1
- 101710125507 Integrase/recombinase Proteins 0.000 claims 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 1
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 1
- 241000710924 Togaviridae Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409228P | 2016-10-17 | 2016-10-17 | |
| US62/409,228 | 2016-10-17 | ||
| JP2019520535A JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
| PCT/US2017/054928 WO2018075235A1 (en) | 2016-10-17 | 2017-10-03 | Recombinant virus replicon systems and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520535A Division JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023134488A JP2023134488A (ja) | 2023-09-27 |
| JP2023134488A5 true JP2023134488A5 (https=) | 2024-03-07 |
Family
ID=60153459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520535A Active JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
| JP2023101803A Withdrawn JP2023134488A (ja) | 2016-10-17 | 2023-06-21 | 組み換えウイルスレプリコン系及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520535A Active JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11364310B2 (https=) |
| EP (1) | EP3526332B1 (https=) |
| JP (2) | JP7382230B2 (https=) |
| KR (1) | KR102718353B1 (https=) |
| CN (1) | CN110073002B (https=) |
| AU (1) | AU2017347725B2 (https=) |
| BR (1) | BR112019007433A2 (https=) |
| ES (1) | ES2993107T3 (https=) |
| MX (1) | MX2019004499A (https=) |
| WO (1) | WO2018075235A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| KR102718353B1 (ko) * | 2016-10-17 | 2024-10-15 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
| JP7788787B2 (ja) | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| WO2019143949A2 (en) | 2018-01-19 | 2019-07-25 | Synthetic Genomics, Inc. | Induce and enhance immune responses using recombinant replicon systems |
| CA3091478A1 (en) | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| KR20210074314A (ko) | 2018-10-08 | 2021-06-21 | 얀센 파마슈티칼즈, 인코포레이티드 | 생체치료제의 투여를 위한 알파바이러스 기반 레플리콘 |
| US12496274B2 (en) | 2018-11-14 | 2025-12-16 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US20220313815A1 (en) | 2019-06-20 | 2022-10-06 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| WO2021138447A1 (en) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| WO2021183563A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| EP4119166A4 (en) | 2020-03-12 | 2024-06-05 | Institute for Basic Science | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition |
| CA3172489A1 (en) | 2020-03-23 | 2021-09-30 | Amit KHANDHAR | Nanoemulsion compositions and methods for delivery of nra |
| EP4135757A1 (en) | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| WO2021229450A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| AU2021271300A1 (en) | 2020-05-11 | 2023-02-02 | Janssen Pharmaceuticals, Inc. | RNA replicon encoding a stabilized corona virus spike protein |
| EP4176087A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN116367854A (zh) | 2020-07-08 | 2023-06-30 | 杨森科学爱尔兰无限公司 | 针对hbv的rna复制子疫苗 |
| PH12023550246A1 (en) * | 2020-07-31 | 2024-06-24 | Replicate Bioscience Inc | Modified chikungunya viruses and sindbis viruses and uses thereof |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| CN112458064A (zh) * | 2020-11-20 | 2021-03-09 | 广西大学 | 盖他病毒全长感染性克隆、复制子系统及其制备和应用 |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
| EP4367253A4 (en) * | 2021-07-09 | 2025-06-04 | Replicate Bioscience, Inc. | Modified eastern equine encephalitis viruses, self-replicating rna constructs, and uses thereof |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| EP4405372A4 (en) | 2021-09-22 | 2026-01-14 | Hdt Bio Corp | SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| KR20240096468A (ko) | 2021-09-22 | 2024-06-26 | 에이치디티 바이오 코포레이션 | 감염병에 대한 rna 백신 |
| WO2023217988A1 (en) | 2022-05-12 | 2023-11-16 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| EP4553164A2 (en) * | 2022-07-08 | 2025-05-14 | Immorna (Hangzhou) Biotechnology Co., Ltd. | Modified self-replicating mrna |
| US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
| EP0165942A1 (en) | 1983-12-23 | 1986-01-02 | Monash University | PRODUCTION OF HUMAN INTERFERON-$g(a) |
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| WO1990006370A1 (en) | 1988-12-01 | 1990-06-14 | The Trustees Of The University Of North Carolina | Synthetic interleukin-6 |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| DK0726758T3 (da) | 1993-08-02 | 2003-03-03 | Scripps Research Inst | Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
| DE19712889A1 (de) | 1997-03-27 | 1998-10-01 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| JP2001520537A (ja) | 1997-04-03 | 2001-10-30 | エレクトロフェクト・アクティーゼルスカブ | 医薬品と核酸の骨格筋への導入方法 |
| US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
| HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| US5958060A (en) | 1998-01-02 | 1999-09-28 | General Electric Company | Method and apparatus for clock control and synchronization |
| EP1100579B1 (en) | 1998-07-13 | 2015-09-02 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
| US20040213805A1 (en) | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
| US6982087B2 (en) | 2000-09-07 | 2006-01-03 | The University Of North Carolina At Chapel Hill | Vectors derived from South African Arbovirus No. 86 |
| US6538922B1 (en) | 2000-09-27 | 2003-03-25 | Sandisk Corporation | Writable tracking cells |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| AU2002242016A1 (en) | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
| EP1278382B1 (en) | 2001-07-19 | 2007-02-14 | Telefonaktiebolaget LM Ericsson (publ) | Method and apparatus for solving number portability in origin |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US6943015B2 (en) | 2002-12-12 | 2005-09-13 | Ilya Frolov | Large scale production of packaged alphavirus replicons |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| DE602004021260D1 (de) | 2003-07-11 | 2009-07-09 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| US20050070700A1 (en) | 2003-09-30 | 2005-03-31 | Matthias Giese | Equine arteritis virus vaccine |
| CA2559083C (en) | 2004-03-08 | 2015-06-16 | Ichor Medical Systems, Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
| CN101548014B (zh) | 2006-06-06 | 2012-07-04 | 墨尔本保健公司 | 抗病毒抗性突变的检测和应用 |
| EP2062246A4 (en) * | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| ES2993941T3 (en) | 2006-10-17 | 2025-01-14 | Inovio Pharmaceuticals Inc | Electroporation devices for electroporation of cells in mammals |
| US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
| KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| DK2947149T3 (en) * | 2007-06-21 | 2018-06-06 | Alphavax Inc | ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION |
| US20110110974A1 (en) | 2007-10-29 | 2011-05-12 | Erik Depla | Methods and kits for inducing a ctl response using a prime boost regimen |
| TWI555531B (zh) | 2009-08-07 | 2016-11-01 | 傳斯堅公司 | 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物 |
| EP2519266B1 (en) | 2009-12-31 | 2017-07-26 | Medigen, Inc. | Infectious dna vaccines against chikungunya virus |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| DK2655621T3 (en) | 2010-12-20 | 2018-08-13 | Massachusetts Gen Hospital | Polycomb-associated non-coding RNAS |
| CN103442732B (zh) | 2011-02-11 | 2017-04-12 | 宾夕法尼亚大学托管会 | 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗 |
| KR102081868B1 (ko) | 2011-06-28 | 2020-02-26 | 이노비오 파마수티컬즈, 인크. | 최소 침습 피부 전기천공 장치 |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| EP2932993B1 (en) | 2012-12-13 | 2017-03-29 | Panasonic Healthcare Holdings Co., Ltd. | Medicament injection device |
| WO2014170493A2 (en) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| WO2016020538A1 (en) | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| AU2015323944B2 (en) | 2014-10-01 | 2018-11-29 | Inovio Pharmaceuticals, Inc. | Vaccines having an antigen and interleukin-21 as an adjuvant |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| KR20180004820A (ko) | 2015-05-15 | 2018-01-12 | 큐어백 아게 | 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법 |
| EP4137150A1 (en) | 2015-08-03 | 2023-02-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
| WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| EP3436139B1 (en) | 2016-03-28 | 2025-04-30 | PapiVax Biotech, Inc. | METHOD AND APPARATUS FOR ADMINISTERING THERAPEUTIC AGENTS |
| US11324819B2 (en) | 2016-04-06 | 2022-05-10 | University Of Washington | Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| KR102718353B1 (ko) | 2016-10-17 | 2024-10-15 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
| JP7788787B2 (ja) | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| US11471527B2 (en) | 2017-06-05 | 2022-10-18 | Beacle Inc. | Virus-like particles including HBs-L antigen protein for causing immune response against HBV |
| CN117866990A (zh) | 2017-11-16 | 2024-04-12 | 华盛顿大学 | 使用HBV包膜蛋白的HBV PreS1和/或PreS2和/或S-HBsAg区域的治疗乙型肝炎病毒（HBV）的疫苗 |
| ES2963179T3 (es) | 2017-12-19 | 2024-03-25 | Janssen Sciences Ireland Unlimited Co | Vacunas contra el virus de la hepatitis b (VHB) y usos de las mismas |
| WO2019143949A2 (en) * | 2018-01-19 | 2019-07-25 | Synthetic Genomics, Inc. | Induce and enhance immune responses using recombinant replicon systems |
-
2017
- 2017-10-03 KR KR1020197013847A patent/KR102718353B1/ko active Active
- 2017-10-03 WO PCT/US2017/054928 patent/WO2018075235A1/en not_active Ceased
- 2017-10-03 ES ES17787724T patent/ES2993107T3/es active Active
- 2017-10-03 EP EP17787724.8A patent/EP3526332B1/en active Active
- 2017-10-03 AU AU2017347725A patent/AU2017347725B2/en not_active Ceased
- 2017-10-03 CN CN201780075817.7A patent/CN110073002B/zh active Active
- 2017-10-03 US US15/723,658 patent/US11364310B2/en active Active
- 2017-10-03 BR BR112019007433-3A patent/BR112019007433A2/pt unknown
- 2017-10-03 JP JP2019520535A patent/JP7382230B2/ja active Active
- 2017-10-03 MX MX2019004499A patent/MX2019004499A/es unknown
-
2022
- 2022-06-13 US US17/806,581 patent/US20230126773A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101803A patent/JP2023134488A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023134488A5 (https=) | ||
| JP2019530466A5 (https=) | ||
| JP4790984B2 (ja) | アルファウイルスレプリコンベクター系 | |
| JP5627464B2 (ja) | アルファウイルス粒子を生成する方法 | |
| EP1141361B1 (en) | Compositions and methods for packaging of alphavirus vectors | |
| EP2305299B1 (en) | Chimeric alphavirus replicon particles | |
| US6692750B1 (en) | Alphavirus expression vector | |
| CA2410948C (en) | Method for the purification of alphavirus replicon particles | |
| US9255126B2 (en) | Chimeric alphavirus replicon particles | |
| AU2002303330A1 (en) | Chimeric alphavirus replicon particles | |
| JP2015527296A5 (https=) | ||
| JP2005515755A5 (https=) | ||
| CA2461380A1 (en) | Hepatitis c virus vaccine | |
| WO2008119827A1 (en) | Transreplicase constructs | |
| EP2331557B1 (en) | Alphavirus packaging cell lines | |
| Raffo et al. | Construction of tobacco mosaic virus subgenomic replicons that are replicated and spread systemically in tobacco plants | |
| EP1029069B1 (en) | Alphavirus vectors | |
| CN115433741A (zh) | 盖他病毒为载体表达报告蛋白的重组病毒的构建方法 | |
| JPWO2019123018A5 (https=) | ||
| US6616929B1 (en) | Swine vesicular disease virus expression vectors | |
| HK1155984A (en) | Chimeric alphavirus replicon particles |